Using Tiny Particles to Deliver Temozolomide and PD-L1 Silencing Molecules to Change Drug-Resistant and Immune-Suppressing Environments in Brain Tumors

TMZ/siPD-L1@GLPN/dsb significantly inhibited the growth of orthotopic TMZ-resistant glioblastoma and extended survival time in rats.

• A nanoparticle formulation was created to deliver both temozolomide and siPD-L1 to resistant glioblastoma tissue.
• This formulation increased the percentage of T cells producing interferon-gamma, enhancing T-cell activity against the tumor.
• It also decreased the presence of regulatory T cells, which are associated with immune suppression.
• The treatment reduced the expression of a protein linked to DNA repair, potentially increasing sensitivity to temozolomide.
• Overall, the nanoparticle approach may help overcome resistance and improve outcomes in glioblastoma therapy.

Simplified